Frailty in Pediatric and Young Adult Cancer Survivors: From Bench to Bedside
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".
Deadline for manuscript submissions: closed (10 October 2022) | Viewed by 23202
Special Issue Editor
Interests: pediatrics; hematology; oncology; pharmacology; molecular and cellular biology
Special Issue Information
Dear Colleagues,
One of the greatest successes of the field of medicine is the improvement of survival among children with cancer, with the 5-year survival rate now exceeding 80%. Unfortunately, those who are successfully treated for their primary malignancy experience increased morbidity and mortality rates compared to the general population, related to chemotherapy, radiotherapy, or both. Childhood cancer survivors are at an especially increased risk for frailty. The frailty phenotype, which identifies individuals who are highly vulnerable to adverse health outcomes, often precedes the onset of chronic disease and is a predictor of early mortality. In the elderly, frailty is influenced by lifestyle and genetics, while in young adult survivors of cancer, reduction in physiologic reserve is more likely related to organ system damage following treatments. Frailty pathogenesis can be partially explained by an imbalance between pro-inflammation and anti-inflammation, which results in inflamm-aging with a low chronic pro-inflammatory status.
This Special Issue will highlight the biological mechanisms driving the development of age-related morbidities (such as osteoporosis, obesity, infertility, and cardiovascular diseases) in childhood cancer survivors, to facilitate the identification of the early frailty markers needed to prevent this process.
Prof. Francesca Rossi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer survivors
- frailty
- inflamm-aging
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.